PAVM

$4.95+$0.53 (+12.59%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$30.1M

7M shares

52-week range

$3.85 – $28.44

4% from low

Sector

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Exchange

NASDAQ

Change$-2690.76

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$340000	+664.0%	$-3.14	$-4.03–$-2.25	—	1
2027	$652500	+91.9%	$-1.28	$-1.64–$-0.92	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-14	$-0.47	$-0.87	-85.1%
2026-05-15	$-0.69	$-4.42	-540.6%
2026-03-26	$-4.50	$-2.05	+54.4%
2025-11-13	$-6.01	$-8.41	-39.9%
2025-08-14	$-0.25	$-0.05	+80.0%
2025-05-15	$-0.29	$-0.07	+75.9%
2025-03-25	$-0.40	$-0.06	+85.0%
2024-11-13	$-1.30	$-0.54	+58.5%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
PAVMPAVmed Inc.	$4.74	+12.86%	$30M	—
ADVBAdvanced Biomed Inc. Common Stock	$8.58	+12.89%	$12M	—
APVOAptevo Therapeutics Inc.	$3.40	-2.86%	$7M	—
BMRABiomerica, Inc.	$1.62	+3.18%	$5M	—
BNRBurning Rock Biotech Limited	$9.29	-6.45%

PAVmed Inc. Common Stock

PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.

www.pavmed.com

Employees: 41
IPO / List date: Apr 28, 2016
HQ: NEW YORK, NY

Held by traders on TradeandTell

No one on the platform currently holds PAVM.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in PAVM as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Stock splits

Execution date	Ratio
2026-01-02	1-for-30reverse
2023-12-07	1-for-15reverse

Recent trades on TradeandTell

No one on the platform has traded PAVM yet.

$PAVM chatter on StockTwits

2626@tds_8m
$LUCD I know we have some $PAVM holders here still... "Veris accelerated its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission. Lucid secured an important new commercial coverage policy for EsoGuard while continuing to advance its broader commercial initiatives. And, our relaunched medical device portfolio is on track with PortIO and Octeris progressing toward key milestones." https://ir.pavmed.com/2026-08-14-PAVmed-Provides-Business-Update-and-Reports-Second-Quarter-2026-Financial-Results
View on StockTwits ↗
Mike Smith@trout290zzaam9m
$PAVM Not sure if this means anything but here it is anyway. https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=320272711&type=PDF&symbol=PAVM&cdn=0fa2272bf6ba8999697a2d48bf178efb&companyName=PAVmed+Inc.&formType=SCHEDULE+13G%2FA&dateFiled=2026-08-13
View on StockTwits ↗
2626@tds_9m
$PAVM "Veris accelerated its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission. Lucid secured an important new commercial coverage policy for EsoGuard while continuing to advance its broader commercial initiatives. And, our relaunched medical device portfolio is on track with PortIO and Octeris progressing toward key milestones." https://ir.pavmed.com/2026-08-14-PAVmed-Provides-Business-Update-and-Reports-Second-Quarter-2026-Financial-Results
View on StockTwits ↗
Diamond Options@theoptionsplug5h
THINGS TO WATCH, FRIDAY, AUGUST 14TH 👁️ $BMY $RLX $OTLK $PAVM $SPY
View on StockTwits ↗
Stocktwits Earnings@StocktwitsEarnings13h
$PAVM Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.87 up 96.06% YoY • Reported revenue of $0.03M up 450.00% YoY
View on StockTwits ↗
Jeff McDowell, CMT@Synaptric15h
Tomorrow morning's earnings list has no Tech but plenty of Biotech and Medical Devices should be interesting. $QNRX in the Extremely Bullish zone after beginning Neutral. $OTLK in the Bearish zone after beginning the period in Extremely Bullish zone. $TMS downwardly sloped past few days to sit a the lowest sentiment. Nothing is in the Neutral zone. $LFWD $PAVM
View on StockTwits ↗
2626@tds_18h
$PAVM volume really picking up the past 3 sessions.
View on StockTwits ↗
Corey Workman@cwork19h
$LUCD $PAVM 💯💯💯
View on StockTwits ↗
Quantumup@Quantumup20h
Needham reiterated $LUCD Buy-$3 and said We Think It's Very Likely That CMS Will Issue A Draft Local Coverage Determination (LCD) Covering EsoGuard This Year. $CSTL MDT MYGN GRAL GH $PAVM NTRA Here's what else Needham said in its note to investors: In 2Q26, EsoGuard test volume grew 1% Y/Y to 2,770. LUCD's 2Q26 revenue came in above consensus and its operating expenses were below our estimate. LUCD ended 2Q26 with ~$33M of cash as its cash burn decreased moderately from 1Q26. Given LUCD's published data and positive Contractor Advisory Committee (CAC) Meeting on 9/4/25, we think it's very likely that CMS will issue a draft Local Coverage Determination (LCD) covering EsoGuard this year. We expect LUCD's revenue growth to increase and to narrow the gap with EsoGuard test volume growth as it gains coverage from Medicare and other insurers, and we reiterate our Buy rating.
View on StockTwits ↗
Frankie J@BigJuicy23h
$LUCD you can’t make this shit up… still NO draft LCD omggggggg $PAVM
View on StockTwits ↗
Harry Bigcock@Thegame70001d
$PAVM
View on StockTwits ↗
dave@dmc43212d
$LUCD If you look at LUCD through the lens of verifiable facts then it all becomes clear. They can not sell. They have failed all 5 times they have tried. If Lishan and Dennis want their roughly $2m package EACH ANNUALLY they need it to be broken across two companies, because $PAVM does nothing. If you have meager sales of a couple of millions a quarter it's embarrassing. But Lishan and Dennis INDIVIDUALLY are paid MULTIPLES EVERY MONTH of what PAVM's ANNUAL Revenue is. If you take Lishan, Dennis and Shaun O'Neill that is a fully loaded cost of over $6m annually. That is more than LUCD's Revenues. The VERY FAT & HAPPY not so LITTLE PIGGIES will feast on retail investors cash for as long as you let them. Think of it over 5 years that's $30M for what progress? Actual measurable progress. NONE. Speak to even one achievements or milestone they themselves set that involves selling or marketing that they have met The ones they can meet is when they pay someone to do something
View on StockTwits ↗
g3ngar.@g3ngar2d
$PAVM
View on StockTwits ↗
Frankie J@BigJuicy3d
$LUCD $PAVM if the LCD isn’t released by 8/31 I’m going to lose my mind.
View on StockTwits ↗
Frankie J@BigJuicy3d
$PAVM .02 cents soon I guesss I’ll have another massive capital loss
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.